AstraZeneca says tests at the end of the Covid-19 vaccine stage were “extremely effective” in preventing the disease. Photo / AP
AstraZeneca said today that the Covid-19 vaccine trials developed with the University of Oxford at the end of the stage were “extremely effective” in preventing disease.
The results are based on an intermediate analysis in Britain and Brazil of the vaccine developed by the University of Oxford and manufactured by AstraZeneca.
No hospitalizations or severe cases of Covid-19 were reported in those receiving the vaccine, AstraZeneca said.
“These findings show that we have an effective vaccine that will save many lives. Remarkably, one of our dosing regimens may be about 90% effective,” said Professor Andrew Pollard, lead researcher on the study.
The trial looked at two different treatments – a half dose of the vaccine followed by a full dose at least a month apart was 90% effective. A second regimen using two full doses at one month intervals was 62% effective. The combined results showed an average efficiency of 70%.
“The efficacy and safety of this vaccine confirm that it will be very effective against Covid-19 and will have a direct impact on this public health emergency,” said Pascal Soriot, CEO of AstraZeneca.
“In addition, our simple vaccine supply chain and our non-profit commitment and our commitment to broad, fair and timely access mean that it will be affordable and globally available, delivering hundreds of millions of doses upon approval.”
Two other pharmacists, Pfizer and Moderna, last week reported preliminary results from late-stage trials that showed Covid-19 vaccines were almost 95% effective.